All In Biotech

Drug Trial Radar · NCT06933914

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of MY008211A Tablets in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 30, 2024

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

  • MY008211A tabletsDrug

    Participants will receive MY008211A at a dose of 400 mg orally b.i.d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with adverse events, safety laboratory parameters, vital signs, ECG.Time frame: About 100 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences)

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.